ERBB2 and breast cancer: This strategy may result effective across different breast cancer setting, In specific regard to the advanced setting for postmenopausal HR+HER2-breast cancer, such an approach may result of particular interest in re-defining the therapeutic continuum for candidates to endocrine therapy following the FDA approval of the cycline dependent inhibitor palbociclib in combination with endocrine agent [28].